45
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The pathway leading from amyloid-β deposition to cognitive impairment is believed to be a cornerstone of the pathogenesis of Alzheimer's disease (AD). However, what drives amyloid buildup in sporadic nongenetic cases of AD is still unknown. AD brains feature an inflammatory reaction around amyloid plaques, and a specific subset of the gut microbiota (GMB) may promote brain inflammation. We investigated the possible role of the GMB in AD pathogenesis by studying the association of brain amyloidosis with (1) GMB taxa with pro- and anti-inflammatory activity; and (2) peripheral inflammation in cognitively impaired patients. We measured the stool abundance of selected bacterial GMB taxa (Escherichia/Shigella, Pseudomonas aeruginosa, Eubacterium rectale, Eubacterium hallii, Faecalibacterium prausnitzii, and Bacteroides fragilis) and the blood expression levels of cytokines (pro-inflammatory cytokines: CXCL2, CXCL10, interleukin [IL]-1β, IL-6, IL-18, IL-8, inflammasome complex (NLRP3), tumor necrosis factor-alpha [TNF-α]; anti-inflammatory cytokines: IL-4, IL-10, IL-13) in cognitively impaired patients with (n = 40, Amy+) and with no brain amyloidosis (n = 33, Amy-) and also in a group of controls (n = 10, no brain amyloidosis and no cognitive impairment). Amy+ patients showed higher levels of pro-inflammatory cytokines (IL-6, CXCL2, NLRP3, and IL-1β) compared with both controls and with Amy- patients. A reduction of the anti-inflammatory cytokine IL-10 was observed in Amy+ versus Amy-. Amy+ showed lower abundance of E. rectale and higher abundance of Escherichia/Shigella compared with both healthy controls (fold change, FC = -9.6, p < 0.001 and FC = +12.8, p < 0.001, respectively) and to Amy- (FC = -7.7, p < 0.001 and FC = +7.4, p = 0.003). A positive correlation was observed between pro-inflammatory cytokines IL-1β, NLRP3, and CXCL2 with abundance of the inflammatory bacteria taxon Escherichia/Shigella (rho = 0.60, p < 0.001; rho = 0.57, p < 0.001; and rho = 0.30, p = 0.007, respectively) and a negative correlation with the anti-inflammatory E. rectale (rho = -0.48, p < 0.001; rho = -0.25, p = 0.024; rho = -0.49, p < 0.001). Our data indicate that an increase in the abundance of a pro-inflammatory GMB taxon, Escherichia/Shigella, and a reduction in the abundance of an anti-inflammatory taxon, E. rectale, are possibly associated with a peripheral inflammatory state in patients with cognitive impairment and brain amyloidosis. A possible causal relation between GMB-related inflammation and amyloidosis deserves further investigation.

          Related collections

          Author and article information

          Journal
          Neurobiol. Aging
          Neurobiology of aging
          Elsevier BV
          1558-1497
          0197-4580
          Jan 2017
          : 49
          Affiliations
          [1 ] Biological Psychiatry Laboratory, IRCCS Fatebenefratelli, Brescia, Italy; King's College London, Institute of Psychiatry, London, UK. Electronic address: acattaneo@fatebenefratelli.eu.
          [2 ] Biological Psychiatry Laboratory, IRCCS Fatebenefratelli, Brescia, Italy.
          [3 ] Laboratory of Neuroimaging and Alzheimer's Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
          [4 ] Nuclear Medicine, Poliambulanza Foundation, Istituto Ospedaliero, Brescia, Italy.
          [5 ] Nuclear Medicine, University of Brescia and Spedali Civili di Brescia, Brescia, Italy.
          [6 ] Biological Psychiatry Laboratory, IRCCS Fatebenefratelli, Brescia, Italy; European Foundation Biomedical Research (FERB), Center of Excellence Alzheimer, Ospedale Briolini, Gazzaniga, Bergamo, Italy.
          [7 ] Department of Medicine and Rehabilitation, Istituto Clinico Sant'Anna, Brescia, Italy.
          [8 ] Neurology Unit, Istituto Clinico Città di Brescia, Brescia, Italy.
          [9 ] Neurology Unit, Ospedale di Vallecamonica Esine, Brescia, Italy.
          [10 ] Neurology Unit, Ospedale Maggiore di Crema, Cremona, Italy.
          [11 ] European Foundation Biomedical Research (FERB), Center of Excellence Alzheimer, Ospedale Briolini, Gazzaniga, Bergamo, Italy.
          [12 ] Alzheimer Evaluation Unit, Istituto Ospedaliero di Sospiro ONLUS Foundation, Cremona, Italy.
          [13 ] Department of Rehabilitation, Casa di Cura Ancelle della Carità, Cremona, Italy.
          [14 ] Alzheimer Evaluation Unit, Hospice Santa Maria Ausiliatrice ONLUS Foundation, Bergamo, Italy.
          [15 ] Alzheimer Evaluation Unit, Casa di Cura Figlie di S. Camillo, Cremona, Italy.
          [16 ] Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland.
          [17 ] Stemedica International SA, Lausanne, Switzerland.
          [18 ] Neurology Unit, Department of Medical and Experimental Sciences, University of Brescia, Brescia, Italy.
          [19 ] Laboratory of Neuroimaging and Alzheimer's Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals, Geneva, Switzerland; Memory Clinic, University Hospitals and University of Geneva, Geneva, Switzerland.
          Article
          S0197-4580(16)30197-X
          10.1016/j.neurobiolaging.2016.08.019
          27776263
          118f0c1a-264d-4ed0-94d8-899f01cc0f0b
          History

          Brain amyloidosis,Cognitive impairment,Gut microbiota,Inflammation,Neurodegeneration

          Comments

          Comment on this article